Private credit has faced negative press and underperformance, but institutional clients are adding exposure, using fear as an opportunity for patient investors, and it could be a good time to consider this asset class.
Healthcare and biotech are overlooked beneficiaries of AI, which can accelerate drug development with more accurate results, making them attractive investments compared to tech.
Healthcare and biotech are overlooked beneficiaries of AI, which can accelerate drug development with more accurate results, making them attractive investments compared to tech.